+

WO1997013503A9 - Synthese de nanoparticules medicamenteuses par sechage par pulverisation - Google Patents

Synthese de nanoparticules medicamenteuses par sechage par pulverisation

Info

Publication number
WO1997013503A9
WO1997013503A9 PCT/US1996/016417 US9616417W WO9713503A9 WO 1997013503 A9 WO1997013503 A9 WO 1997013503A9 US 9616417 W US9616417 W US 9616417W WO 9713503 A9 WO9713503 A9 WO 9713503A9
Authority
WO
WIPO (PCT)
Prior art keywords
agent
nanoparticles
ethyl
diacetamido
triiodobenzoate
Prior art date
Application number
PCT/US1996/016417
Other languages
English (en)
Other versions
WO1997013503A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to EP96939455A priority Critical patent/EP0862420A4/fr
Publication of WO1997013503A1 publication Critical patent/WO1997013503A1/fr
Publication of WO1997013503A9 publication Critical patent/WO1997013503A9/fr

Links

Definitions

  • the present invention relates to the field of drug manufacture, and, in particular, to the synthesis of therapeutic, diagnostic, analgesic, and antiinflammatory compositions having a median particle size less than about 5000 nm.
  • a drug When a drug is administered into a body, it typically must cross a series of membranes before reaching the site of action where its activity can have a desired effect.
  • oral administration of a drug having a systemic site or sites of action will provide limited or no relief unless the drug crosses the gut wall.
  • the ability of a drug to cross the gut wall can be controlled by the way in which the active substance is formulated.
  • the formulation can also provide control as to the site of action of a given drug, and the rate at which the drug is available at that site. For instance, the same amount of drug could have a different effect when administered as an oral solution than when administered as a tablet because of the differences in the rate at which the drug is absorbed from the gut in the two cases.
  • nanoparticles include the fact that drugs administered as nanoparticles have increased surface areas relative to larger sized drug particles, which correlates with increased absorption and utilization of the drug. Prescot et al., Clin. Pharm. Therap. , 1 1 , 496.
  • naproxen the dextrorotatory isomer of 6-methoxy- ⁇ r-nr.ethyl-2-naphthalene acetic acid.
  • Naproxen has been shown to possess analgesic and anti-inflammatory activity in the treatment of rheumatoid arthritis, for example, for which naproxen nanoparticles can be more effective than aspirin, indomethacin, ibuprofen, and fenoprofen. These nanoparticles are better tolerated, thus enabling more patients to continue with the treatment.
  • nanoparticles are agents for X-ray diagnostic medical imaging.
  • organic nanoparticles such as iodine-substituted ethyl benzoates, iothalamates, metrizoates and iodipamides, have been identified for X-ray contrast imaging because of their low solubility in aqueous media (less than about 10 mg/mL), and not being radioactive.
  • Such nanoparticles provide effective imaging of tissue or fluid sites of the human body for up to 2 h and longer when administered intravenously as aqueous colloidal dispersions for the imaging of blood pool, liver, kidney, bone marrow, lymph nodes and spleen, for example. See EP 0 498 482 A2 and US Patents 5, 1 45,684; 5,298,262; 5,233,995; and 5,302,401 .
  • a novel spray drying method has been developed to synthesize drug nanoparticles having median sizes of less than about 5000 nm. This method involves spray drying different concentrations of the drug dissolved in dimethyl sulfoxide (DMSO),
  • 1 -methyl-2-pyrroIidinone (1 2 MPO), ethanol, or water, with or without surfactants, sugars including sucrose, D( + Hactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol, and stabilizers.
  • this invention relates to how the precursor chemistry can be manipulated that leads to the formation of drug particles as small as less than about 40 nm, and the versatility of the method in mass producing nanocomposite powders, which can be rehydrated in the presence of suitable surfactants including a polaxamer, such as PluronicTM F-68, a polyoxyethylene alcohol, such as Brij ® 30, a nonoxynol, such as igepal CO-520 ® , and TetronicTM 908, and polymeric stabilizers including polyvinyl atcohol-polyvinyl acetate copolymers to form pharmaceutically acceptable drug nanoparticle formulations.
  • suitable surfactants including a polaxamer, such as PluronicTM F-68, a polyoxyethylene alcohol, such as Brij ® 30, a nonoxynol, such as igepal CO-520 ® , and TetronicTM 908, and polymeric stabilizers including polyvinyl atcohol-polyvinyl acetate cop
  • the present invention is directed to a method for synthesizing nanoparticles comprising (a) combining an agent and a matrix material to form a composite mixture; and (b) spray drying the composite mixture, forming a nanocomposite.
  • the matrix material is at least 10% of the nanocomposite.
  • the agent can be a diagnostic, therapeutic, cosmetic, dye, photographic, food, pesticide agent, or metal catalyst.
  • the diagnostic agent is any suitable agent used to diagnose a disease or condition, such as, but not limited to, ethyl 3,5-diacetamido-2,4,6-triiodobenzoate.
  • the therapeutic agent is any suitable agent for the treatment of a disease or condition selected from the group consisting of, but not limited to, an antiinflammatory agent, an antibiotic agent, an antifungal agent, an antiviral agent, an antineoplastic agent, an immunosuppressive agent, an immunostimulatory agent, an odor masking agent, an insect repelling agent, an anesthetic agent, an antiseptic agent, an antioxidant, an antihistamine, an antidiabetic agent, an antiepileptic agent, a muscle relaxant, a stimulant, an antiallergic agent, a liposaccharide complexing agent, a vitamin, a hormone, an anticancer agent, and a cough suppresant.
  • a preferred antiinflammatory agent is naproxen.
  • the nanoparticles of the present invention are formulated as a colloidal suspension, capsule, tablet, or powder.
  • the ratio of agent to matrix material used in the context of the present invention is from about 10: 1 to about less than 1 : 100, as judged from analysis of the nanocomposite; and the agent and matrix material are combined in the presence of organic and aqueous solvents.
  • the present method further comprises atomizing the composite mixture, which preferably forms droplets of from about 1 ⁇ m to about 100 ⁇ m, more preferably from about 1 ⁇ m to about 75 ⁇ m, and yet more preferably from about 1 ⁇ m to about 50 ⁇ m.
  • the nanoparticles produced in the context of the present invention have a median size that is less than about 5000 nm. Preferably, the nanoparticles have a median size of less than about
  • the nanoparticles of the present invention are produced amidst a matrix, wherein the matrix is formed from a matrix material comprising a carbohydrate, a protein, an inorganic salt, a resin, or a Iipid.
  • the carbohydrate is a sugar selected from the group consisting of sucrose, glucose, fructose, mannose, maltose,
  • the carbohydrate can also be selected from the group consisting of cellulose acetate, cellulose acetate phthalate, carboxymethyl cellulose, ethyl cellulose, carboxymethyl cellulose calcium or sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose phthalate, noncrystalline cellulose, starch, and arabinogalactose.
  • the carbohydrate is a natural polysaccharide selected from the group consisting of gum arabic (acacia), gum ghatti, karaya, tragacanth, locust bean, guar and xanthan gum.
  • the inorganic salt is selected from the group consisting of sodium chloride, potassium chloride, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, sodium benzoate, calcium stearate, calcium carbonate, barium sulfate, sodium salicylate, sulfathiazole sodium salt, alumina salts, magnesia salts, alumina-magnesia salts, formed from inter alia aluminum hydroxide, and the like.
  • the protein is collagen, gelatin, or zein.
  • the alumina salts, magnesia salts, alumina-magnesia salts, formed from inter alia aluminum hydroxide, and the like forms a gel.
  • the resin is selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyarylic acid, polyethylene, polymethacrylate, polyamide (nylon), poly [ethylene-vinyl acetate], and shellac;
  • the Iipid is selected from the group consisting of synthetic and natural phospholipids, glyceryl esters, paraffin, carnauba, spermaceti, beeswax, steric acid, stearyl alcohol and glycerol stearates;
  • the protein is gelatin, zein, or collagen.
  • the matrix further comprises a stabilizer, a surface modifier, a disintegrating agent, or a lubricating, which may include compounds listed above.
  • the nanoparticle comprises ethyl 3,5-diacetamido-2,4,6-triiodobenzoate as the diagnostic agent and the nanoparticles have a median size of from about 1 60 nm to about 280 nm.
  • the nanoparticle comprises an antiinflammatory agent such as aspirin, naproxen, indomethacin, ibuprofen, fenoprofen or acetaminophen or an antibiotic agent selected from the group of penicillins, tetracyclins, aminiglycoside antibiotics, and clindamycin.
  • an antiinflammatory agent such as aspirin, naproxen, indomethacin, ibuprofen, fenoprofen or acetaminophen
  • an antibiotic agent selected from the group of penicillins, tetracyclins, aminiglycoside antibiotics, and clindamycin.
  • a preferred embodiment of the present invention provides a method for synthesizing nanoparticles comprising naproxen as the antiinflammatory agent, sucrose as the matrix, poiyvinyl alcohol-polyvinyl acetate copolymers, PluronicTM F-68, or TetronicTM 908, and the nanoparticles have a median particle size of from about
  • Another preferred embodiment of the present invention is a pharmaceutical formulation comprising a nanoparticle synthesized by a method comprising (a) combining an agent and a matrix; and (b) spray drying the combined agent and matrix; and a pharmaceutical carrier.
  • a method comprising (a) combining an agent and a matrix; and (b) spray drying the combined agent and matrix; and a pharmaceutical carrier.
  • Fig. 2 is a diagram relating to the stages of the spray drying process.
  • Fig. 3 is a graph that depicts the results of an energy dispersive analysis by X-ray, demonstrating the presence of the iodine atoms of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP- 1 ) throughout the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate-containing nanoparticles.
  • CMP- 1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
  • Fig. 4 is a graph depicting median particle size as a function of the initial concentration of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate (CMP-1 ).
  • Fig. 5 is a graph depicting median particle size as a function of the initial concentration of PluronicTM F-68.
  • Fig. 6 is a graph depicting the change in particle size distribution of spray dried ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) as a function of sonication time.
  • Fig. 7 is a graph depicting x-ray diffraction results of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) nanoparticles comparing conventionally precipitated powders and spray-dried powders.
  • CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
  • Fig. 8 is a graph depicting x-ray diffraction results of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) nanoparticles generated in the presence or absence of PluronicTM F-68.
  • CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
  • Fig. 9 is a graph depicting x-ray diffraction results of ethyl cellulose powder and spray dried naproxen-ethyl cellulose nanocomposite. DESCRIPTION OF THE INVENTION
  • a nanoparticle is formed substantially of an active agent ("the agent”) and is between about 1 0 nm and about 5000 nm in size.
  • a nanoparticle substantially formed of the agent is a nanoparticle that is at least about 80% by weight composed of the agent, more preferably at least about 90%, yet more preferably at least about 95%, and most preferably at least about 99%; the remainder of the content of a nanoparticle is composed of surface modifiers, surfactants, and other matrix material discussed hereinbelow. (Note that all percentages recited in this specification with respect to proportional content are proportions by weight, unless otherwise labeled) .
  • the nanoparticles synthesized in the context of the present invention are preferably uniform in spatial distribution with respect to the matrix, as seen by electron microscopy. For example, for nanoparticles having a size between about 10 nm and about 100 nm, such nanoparticles are found within about 200 nm to about 500 nm of each other; for nanoparticles having a size between about 200 nm and about 400 nm, such nanoparticles are found within about 400 nm to about 1000 nm of each other; and for nanoparticles having a size between about 1000 nm and about 5000 nm, such nanoparticles are found within about 2000 nm to about 3000 nm of each other.
  • the nanoparticles synthesized in the context of the present invention preferably are uniform in distribution of size for a given set of process parameters used to generate the nanoparticles, which process parameters are further discussed hereinbelow.
  • process parameters are further discussed hereinbelow.
  • at least more than about 10% of the nanoparticles can be synthesized having a given size, more preferably, at least more than about 50% of the nanoparticles can be synthesized having a given size, and yet more preferably, at least more than about 90% of the nanoparticles can be synthesized having a given size.
  • nanoparticles are synthesized dispersed within a matrix within or by which the nanoparticles are formed.
  • Any material included in a nanocomposite that is not a nanoparticle is considered herein to be part of the matrix, and the matrix can be a porous or a dense structure.
  • a suitable matrix material is any chemical, compound, or structure that is a solid at room temperature (i.e., about 25 * C), including but not limited to the examples set forth hereinbelow.
  • the size of a nanoparticle is less than about 5000 nm and at least about 10 nm, preferably less than about 1 000 nm, more preferably less than about 400 nm, and most preferably less than about 250 nm.
  • the material of the matrix (“the matrix material”) is in a solid or solute phase, or the dried product thereof, and forms the aforementioned matrix.
  • the combination of the agent and the matrix material is referred to herein as the "composite mixture,” from which, upon spray drying, is formed the aforementioned nanocomposite.
  • the composite mixture particularly in the presence of a solvent, which, as further discussed below, can be organic or aqueous or both, forms a solution, which is prefered, or a suspension.
  • the particulate matter within the mixture may require further processing to allow formation of nanoparticles of the present invention.
  • the agent is present as particles that are greater or similar to the size of nanoparticles desired, then the present process includes a step to reduce the size of the agent.
  • the matrix material may require a size reduction to assure the desired size of nanocomposite, and of the resultant nanoparticles.
  • Such further processing involves any suitable process for size reduction of such particulate matter, such as, but not limited to, sonication, microfluidization, or milling, or a combination thereof, using methods known to the art.
  • the composite mixture is preferably a solution, although in an alternative embodiment, the composite mixture is a suspension, wherein the suspended particulate matter can be agent or matrix material, and preferably is matrix material only.
  • the composite mixture comprises a sufficient concentration of matrix material that, upon spray drying, a matrix is believed to be formed by the so- treated matrix material.
  • the dissolved agent included in the composite mixture is believed to be contained within pores or upon the surface of the matrix, by which the agent forms nanoparticles in the spray drying process.
  • Matrix material can constitute over 99% of the nanocomposite.
  • the matrix material comprises about 60% of the nanocomposite.
  • the matrix material comprises about a majority of the nanocomposite, more preferably the matrix material comprises about 40% of the nanocomposite, even more preferably the matrix material comprises about 25% of the nanocomposite, yet more preferably the matrix material comprises about 1 5% of the nanocomposite, and most preferably, the matrix material comprises about 10% of the nanocomposite.
  • solvent included with the composite mixture is removed by evaporation, thereby increasing the concentration and viscosity of the matrix material, which in turn restricts the mobility (via diffusion, for example) of the agent while in solution.
  • the matrix is believed to be formed by the matrix material in this process and is believed to confine the distribution of the agent included in the composite mixture within the surface structure of the matrix.
  • the agent is believed to supersaturate and thereafter precipitate as a consequence of inherent properties of the matrix material, such as viscosity, molecular weight, porosity, pore size, and the like.
  • Viscosity of the matrix can range from about 100 cp to about 100,000 cp, preferably from about 1 00 to about 5,000 cp, and more preferably from about 100 cp to about 1 ,000 cp.
  • Preferred matrices have a porous structure, which porosity is preferably from about 10% to about 90%, more preferably from about 50% to about 90%.
  • Preferred pore size of the matrix material or resultant matrix is from about 5 nm to about 500 nm, more preferably from about 10 nm to about 100 nm.
  • Spray drying is a process of converting a liquid into a powder by spraying the liquid into a hot drying gaseous medium. This process constitutes: (i) generation of liquid aerosol droplets,
  • the particle morphology also depends on the drying conditions.
  • a particle formed by spray drying of solution is composed of many crystallites.
  • the nature of the solvent and the addition of surfactant to the solution can affect the nucleation and growth processes, and hence the crystallite size.
  • an instantaneous nucleation has to be induced throughout the solution, and agglomeration must be avoided.
  • the residence time of the composite mixture in the spray dryer is no more than about 25 seconds, more preferably no more than about 1 5 seconds, and most preferably no more than about 1 0 seconds.
  • Ostwald ripening must be prevented.
  • hollow particles comprising single crystals or solid single crystals, hollow crust, crystal platelets, or needle-shaped crystal
  • hollow particles comprising single crystals or solid single crystals, hollow crust, crystal platelets, or needle-shaped crystal
  • suitable alterations to the spray drying process with respect to temperature, humidity, solvent evaporation rate, solute solubility, interfacial energy, particle mass and crystal growth rates.
  • evaporation and crystal growth rates and solubility solid single crystal particles or particles consisting of an ensemble of small crystals can be obtained.
  • the particle size and morphology can be varied by altering the initial concentration of the solution, surfactant concentration, and otherwise altering the composite mixture.
  • Spray drying has been employed in the pharmaceutical industry for: (i) drying a variety of heat sensitive biological materials, including plasma, proteins, enzymes, sera, microorganisms and yeasts; (ii) improving the solubility of water-soluble substances; (iii) increasing the flow properties of free-flowing granules for tablet preparation; and (iv) improving the dispersibility of methylcellulose.
  • heat sensitive biological materials including plasma, proteins, enzymes, sera, microorganisms and yeasts
  • improving the solubility of water-soluble substances including plasma, proteins, enzymes, sera, microorganisms and yeasts
  • improving the solubility of water-soluble substances including water-soluble substances; (iii) increasing the flow properties of free-flowing granules for tablet preparation; and (iv) improving the dispersibility of methylcellulose.
  • prior uses of spray drying have not provided nanoparticles of uniform median sizes, such as those of less than about 5000 nm, more preferably of less than about 1 000 nm, yet more preferably of less than about 400 nm, and most preferably of less than about 250 nm; and greater than at least about 10 nm.
  • Nanoparticles of the present invention are preferably prepared in the presence of matrix material that forms a solid at room temperature (about 25 ° C), such as a carbohydrate, including a sugar selected from the group consisting of sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, glucose, fructose, mannose, maltose, sorbitol, and D-mannitol.
  • matrix material that forms a solid at room temperature (about 25 ° C)
  • Nanoparticles are also preferably prepared in the presence of stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; and in the presence of surfactants, including but not limited to a polaxamer, such as PluronicTM F-68 or F-108 (manufactured by BASF- Wyandotte), which is a block copolymer of ethylene oxide and propylene oxide, a polyoxyethylene alcohol, such as Brij ® 30 (manufactured by ICI), a nonoxynol, such as Igepal CO-520 ® (manufactured by GAF), and TetronicTM 908.
  • stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers
  • surfactants including but not limited to a polaxamer, such as PluronicTM F-68 or F-108 (manufactured by BASF- Wyandotte), which is a block copolymer of ethylene oxide and propylene oxide
  • the powder produced by spray drying can be rehydrated to form pharmaceutically acceptable drug nanoparticle formulations with particle size of less than about 5000 nm, preferably less than about 1000 nm, more preferably less than about 400 nm, and most preferably less than about 250 nm.
  • a surface modifier adsorbed on the surface of the nanoparticle is preferably included in the nanoparticle production as well.
  • the present invention is also related to spray drying solutions with different process parameters, including suitable matrix material/agent concentration in the composite mixture, drying temperature, residence time of the composite mixture in the spray dryer, solvent and the presence of surfactant to produce the preferred drug nanoparticles.
  • concentration of the matrix material/agent component of the composite mixture can be any concentration to the extent that the composite mixture remains atomizable and the matrix forms.
  • the composite mixture must be pumpable, which is consistent with the composite mixture having a viscosity of no more than about 300 cp, more preferably no more than about 200 cp, yet more preferably no more than 100 cp.
  • drying temperatures are those that provide for adequate drying such that the nanoparticles are formed, and of a temperature range that the agent does not become inactivated or substantially inactivated.
  • drying temperatures are less than about 275 ° C, preferably about 200 ⁇ C, more preferably about 1 50° C.
  • the drying temperatures are less than about 1 50 ° C, preferably about 125 * C, or 90 " C, or 75 " C, or 50 ° C.
  • a spray drying process incorporates a combination of different temperatures as herein discussed, or a gradient of such temperatures, or any combination thereof.
  • Suitable residence times are those that are sufficiently short so as to prevent phase separation of the components of the composite mixture in the spray dryer.
  • suitable residence times are less than about 25 seconds, more preferably less than about 1 5 seconds, yet more preferably less than about 10 seconds.
  • Preferred surface modifiers can be low molecular weight polymers (molecular weight less than about 2000) including nonionic and ionic surfactants; natural products and various polymers, and high molecular weight (molecular weight less than about 20,000 to about 40,000) steric stabilizers including polyvinyl alcohol-polyvinyl acetate copolymers, for example.
  • the surface modifiers preferably do not chemically react with the agent or itself.
  • Representative nanocomposite host matrices for the drug include without limitation carbohydrates including sugars, e.g., glucose, fructose, lactose, mannitol, sucrose, maltose, trehalose, sorbitol, mannitol, and mannose; celluloses, e.g., cellulose acetate, cellulose acetate phthalate, carboxymethyl cellulose, ethyl cellulose, carboxymethyl cellulose calcium or sodium, carboxymethyl cellulose sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propymethyllcellulose phthalate and noncrystalline cellulose; and other suitable carbohydrates, such as starch and arabinogalactose; suitable proteins, e.g., collagens, zein, and gelatin; inorganic salts, e.g., sodium chloride, potassium chloride, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, sodium
  • the matrix material can be in the form of a gel, as in, for example, alumina-magnesia gels, aluminum hydroxide gel and magnesia gel.
  • Resins useful in the context of the present invention are high polymers of natural or synthetic origin, including those set forth above.
  • Suitable lipids useful in the context of the present invention form porous solid structures at room temperature (about 25 ° C), more preferably at about 50 " C, yet more preferably at about l OO ' C, and even more preferably at about 1 50 ° C.
  • Nanocomposite host matrices particularly useful in the present invention are water-soluble sugars such as sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol; stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; and surfactants such as PluronicTM F-68, Brij ® 30, Igepal CO-520 ® and TetronicTM 908.
  • the amount of a sugar in the nanocomposite particles can vary from about 10 to 90%, preferably
  • Examples of some representative surface modifiers are gelatin, casein, phospholipids, stearic acid, gum acacia, cholesterol, benzalkonium chloride, calcium stearate, magnesium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl esters, e.g., macrogol esters such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, the commercially available TweensTM, such as Tween 80 having formula weight 1309.68 (purchased from Aldrich Chemical Co., Inc., Catalog # 27,436-4) polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphate, sodium dodecyl sulfate, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propymethyll
  • surface modifiers include polyvinylpyrrolidinone, tyloxapol, polaxamers such as PluronicTM F-68 and F-108 (manufactured by BASF-Wyandotte), which are block copolymers of ethylene oxide and propylene oxide, and polyoxamines such as TetronicTM 908 (manufactured by BASF), which is a tetrafunctional block copolymer derived from subsequent addition of propylene oxide and ethylene oxide to ethylenediamine; dextran, lecithin, dialkyl esters of sodium sulfosuccinic acid, such as Aerosol OTTM (manufactured by American Cyanimid), which is a dioctyl ester of sodium sulfosuccinic acid, i.e., do
  • a polysorbate such as TweenTM (manufatured by ICI Specialty Chemicals), and polyethylene glycols, such as CarbowaxTM 3350 and 934 (manufactured by Union Carbide) .
  • Surface modifiers which have been particularly useful include Tetronic 908, the TweensTM, and Pluronic F-68.
  • Other useful surface modifiers include: decanyl-N-methylglucamide, n-decyl 5-D-glucopyranoside, n-decyl ?-D-maltopyranoside, n-dodecyl ?-D-glucopyranoside, n-dodecyl /3-D-maltoside, heptanoyl-N-methylglucomide, n-heptyl ⁇ -D- glucopyranoside, n-heptyl ?-D-thioglucoside, n-hexyl ?-D-glucopyranoside, nananoyl-N-methylglucamide, n-nonyl jff-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl ⁇ -D-giucopyranoside, and n-octyl ?-D-thioglucopyranoside.
  • Surface modifiers useful in the present invention are PluronicTM F-68 (a nonionic solid copolymer of ethylene oxide and propylene oxide), and TetronicTM 908 (a solid nonionic tetrafunctional block copolymer derived from subsequent addition of propylene oxide and ethylene oxide to ethylenediamine).
  • the relative amount of therapeutic or diagnostic agent and surface modifier can vary widely and the optimal amount of surface modifier can depend, for example, upon the therapeutic or diagnostic agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic-lipophilic balance (HLB) of the stabilizer, the surface tension of water solutions of the stabilizer and the melting point of the stabilizer.
  • HLB hydrophilic-lipophilic balance
  • a method for the preparation of a nanoparticle composition includes dissolving a therapeutic or diagnostic agent, optionally a nanocomposite host material, and a surface modifier in a suitable solvent.
  • the resulting solution is atomized into droplets and these droplets are converted into solid particles in a horizontal spray dryer. If a surface modifier or polymeric stabilizer is not present in the as-sprayed particles, it can be admixed thereafter.
  • the liquid medium especially water, can serve as the pharmaceutically acceptable carrier.
  • the method preferably is carried out under aseptic conditions.
  • the particle size corresponds to a number median particle size as measured by the conventional particle size measuring techniques, such as laser light scattering methods.
  • a median particle size means that at least about 50% of the particles have a number average particle size of the specified size when measured by the above-mentioned techniques, which defines the term "d 50 . ". Accordingly, a "median particle size of less than about 5000 nm” means that at least 50% of the particles have a number average particle size of less than about 5000 nm.
  • the median particle size is less than about 1000 nm, more preferably less than about 400 nm, yet more preferably less than about 300 nm, and most preferably less than about 250 nm. It is preferred that at least about 95%, defining "d 9S " and, more preferably, at least about 99%, defining "d 99 " of particles have a median particle size of less than about 400 nm.
  • the surface modifier if not present in the spray dried powder, must be added to the dispersing liquid medium in which the therapeutic or diagnostic agent is essentially insoluble to form a stable formulation.
  • the concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0 to about 60%, and preferably from about 5 to about 30% (w/w).
  • the concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably from about 1 to about 75%, more preferably about 10 to about 60%, and most preferably about 10 to about 30% by weight of the total weight of the drug and the modifier.
  • Nanocomposite host materials particularly useful in the present invention are water-soluble sugars such as sucrose, D( + )-lactose monohydrate, ⁇ -D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol; stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; surfactants such as PluronicTM F-68, Brij ® 30, igepal CO-520 ® and TetronicTM 908.
  • the amount of host materials in the nanocomposite particles can vary from about 10 to about 90%, preferably about 30 to about 90%, more preferably about 40 to about 80%, and most preferably about 50 to about 70% by weight based on the total weight of the drug and host materials.
  • therapeutic agents which satisfy the matrix mediated synthesis of nanoparticles are any agents used to treat a disease or condition, such as, but not limited to analgesic and- antiinflammatory agents including aspirin, naproxen, indomethacin, ibuprofen, fenoprofen and acetaminophen; antibiotic agents including penicillins, tetracyclines, aminiglycoside antibiotics, and clindamycin; immunosuppressive agents, immunostimulatory agents, antifungal agents, antiviral agents, antineoplastic agents, anticancer agents, odor masking agents, insect repelling agents, peptides, immune reagents, anesthetic agents, antiseptic agents, antihistamine agents, antioxidants, antidiabetic agents, antiepileptic agents, muscle relaxants, stimulants, vitamins, hormones, cough suppressants, anti-
  • analgesic and- antiinflammatory agents including aspirin, naproxen, indomethacin, ibuprofen,
  • Such therpeutic agents can be peptides, proteins, nucleic acids of any suitable size, carbohydrates, lipids, steroids, and the like, and combinations thereof as covendedly combined or by admixture.
  • Such therapeutic agents can also be tissue growth factors, liposaccharide complexing agents, and the like.
  • the amount of drug in the nanocomposite particles can vary from about 10 to about 90%, preferably about 10 to about 70%, more preferably about 20 to about 60%, and most preferably about 30 to about 50% by weight based on the total weight of the drug and host materials.
  • the composite approach can offer a number of advantages in terms of reducing the particle size, yield, production rate and phase distribution flexibility. Since sugars such as sucrose, D( + Hactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol, surfactants such as Pluronic F-68, and Tetronic 908, and stabilizers polyvinyl alcohol-polyvinyl acetate copolymers are highly soluble in water, but not the ethyl 3,5-diacetamido-2,4,6- triiodobenzoate and naproxen crystals, dispersing the composite particles in water with about 0.03 wt.% PluronicTM F-68 and removing the aqueous sugar solutions result in the formation of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanocrystals.
  • Pluronic F-68 and Tetronic 90
  • the concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0 to about 60%, and preferably from about 5 to about 30% (w/w) .
  • the concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably from about 1 to about 75%, more preferably about 10 to about 60%, and most preferably about 0 to about 30% by weight of the total weight of the drug and the modifier.
  • nanoparticles that are synthesized by the method of the invention, which include a therapeutic or diagnostic agent
  • drug nanoparticles can be administered orally, topically, rectally, nasally, vaginally, by inhalation, for example by use of an aerosol, or parenterally, i.e. intramuscularly, subcutaneously, intraperitoneally, intraventricularly, or intravenously.
  • the drug nanoparticles are administered alone, or they are combined with a pharmaceutically-acceptable carrier or excipient according to standard pharmaceutical practice.
  • the drug nanoparticles are used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like.
  • carriers that are used include lactose, sodium citrate and salts of phosphoric acid.
  • Various disintegrants, such as starch, and lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc are commonly used in tablets.
  • useful diluents are lactose and high molecular weight polyethylene glycols.
  • sterile suspensions of the drug nanoparticles are usually prepared, and the pH of the suspensions are suitably adjusted and buffered.
  • the total concentration of solutes are controlled to render the preparation isotonic.
  • ointments or droppable liquids are delivered by ocular delivery systems known to the art, such as applicators or eye droppers.
  • Such compositions include mucomimetics, such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or polylvinyl alcohol), preservatives, such as sorbic acid, EDTA or benzylalkonium chloride, and the usual quantities of diluents and/or carriers.
  • diluents and/or carriers are selected as appropriate for formation of an aerosol.
  • the drug nanoparticles are administered in an effective amount.
  • An effective amount is an amount effective to either ( 1 ) reduce the symptoms of the disease sought to be treated or (2) induce a pharmacological change relevant to treating or preventing or diagnosing the disease sought to be treated or prevented or diagnosed.
  • FIG. 1 This example illustrates spray drying equipment as used in the context of the present invention.
  • Spray drying equipment used for demonstrations of the present invention is schematically displayed in Fig. 1 .
  • the spray drying equipment consists of a feed delivery system, a nebulizer, a glass drying tube of about 3 meters in length with 5-temperature zones, T, to T 5 , a filter to collect the powder, a liquid N 2 trap for the solvent, and a vacuum pump.
  • This spray dryer is similar to parallel
  • the 5-temperature zones, T to T 5 ranged in temperature from about
  • This example illustrates one embodiment of the- present invention, whereby nanoparticles were generated using the spray drying equipment of Example 1 .
  • Solutions with ethyl 3,5-diacetamido-2,4,6-triiodobenzoate manufactured by Nanosystems, Inc., Collegeville, PA
  • sugar 1 :2 and 1 :9 wt. % were prepared by dissolving ethyl 3,5-diacetamido-2,4,6-triiodobenzoate and one of the following sugars; sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol in DMSO and water by the following procedure: In a 200 mL bottle, 5 g ethyl
  • 3,5-diacetamido-2,4,6-triiodobenzoate was dissolved in 100 mL DMSO. To this solution, 10 g of one of the aforementioned sugars was dissolved in 10 mL water, and was added drop by drop, and resulted in a clear solution.
  • the moistened solid was suspended in a finely divided state in a medium velocity (20 to 1 00 m - s "1 ) hot nitrogen stream.
  • the resulting dried, fine particulate material i.e., the nanocomposite powder, was collected in the filter by maintaining a filter pressure draft of about 0.01 to 0.05 MPa by using the vacuum pump, as depicted in Fig. 1 .
  • the residence time for a droplet in the glass tube was 2 to 10 seconds.
  • the spray dried nanocomposite powders were dispersed in water with surfactant by sonication using an ultrasonic power supply having a frequency of either 20 or 80 kHz for about 1 to about 5 min. From particle size analysis, it was determined that these nanocomposite powders, when rehydrated in water with 0.1 % (w/v) PluronicTM F-68 surfactant, yielded ethyl 3,5-diacetamido-2,4,6- triiodobenzoate nanoparticle formulations with median particle diameters of 1 60 to 275 nm. Table 1 lists the ethyl
  • Ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:sucrose (1 :2 wt. %) nanocomposite particles were analyzed by scanning and transmission electron microscopy, SEM and TEM, respectively, and energy dispersive analysis by x-ray.
  • the SEM micrographs showed agglomerates of composite particles, whereas the TEM micrographs (not shown) showed the distribution of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate particles (which are electron dense, thus darker structures) and sucrose particles (less electron dense relative to the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate, thus lighter structures) to be uniform in the nanocomposite.
  • the ethyl 3,5-diacetamido-2,4,6-t ⁇ odobenzoate particle size as seen in the micrographs varied from about 1 5 nm to about 45 nm, whereas the sucrose particle size ranged from about 90 nm to about 200 nm.
  • the energy dispersive analysis by x-ray demonstrated the presence of iodine atoms of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate throughout the composite particles, as can be seen in the graph of Fig. 3, wherein the x-axis is labelled as keV for x-ray energy levels and peaks are labeled to identify those associated with carbon (C), oxygen (O), iron (Fe), copper (Cu), and iodine (I) .
  • 3,5-diacetamido-2,4,6-triiodobenzoate particle size a pressure atomizer was used.
  • the diameter of droplets generated from the pressure atomizer was 10 to 30 ⁇ m, whereas the solution flow rate was varied between 1 .5 to 3 mL/min.
  • These atomized droplets were transported through the glass tubes of the spray drying equipment with 5-temperature zones as depicted in Fig. 1 .
  • the maximum temperature of the glass tube was 250°C. Evaporation of water and DMSO within the tube resulted in air-born ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:sugar nanocomposite particles. These particles were collected in a finely woven Gortex bag (Grade P-80; purchased from Standard Filter Co).
  • CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
  • This example illustrates production of nanoparticles using the present invention.
  • Solutions with 1 to 20 g ethyl 3, 5-diacetamido-2,4,6- t ⁇ iodobenzoate per 100 mL l -methyl-2-pyrrol ⁇ d ⁇ none ( 1 2 MPO) were prepared by the following procedure. In a 250 mL beaker, 5 g ethyl 3,5-diacetamido-2,4,6-triiodobenzoate and 100 mL 1 2 MPO and 1 .5 g were added, and sonicated for 1 5 minutes. Sonication accelerated the dissolution of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate in 1 2 MPO.
  • solutions of 5 g ethyl 3,5-diacetamido-2,4,6-triiodobenzoate per 100 mL 12 MPO with either 0.1 5 g or 1 .5 g PluronicTM F-68 were prepared as described above.
  • These ethyl 3,5-diacetamido-2,4,6-triiodobenzoate solutions were spray dried using the spray drier described in Example 1 .
  • the maximum drying temperature was 250°C to produce the nanoparticles.
  • the as-produced fine powders were collected in a filter bag.
  • Tables 3-6 list the particle sizes of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate spray dried from the aforementioned ethyl 3,5-diacetamido-2,4,6-triiodobenzoate ("CMP- 1 ”) per 100 mL 1 2 MPO solutions, as well as other parameters measured.
  • CMP- 1 ethyl 3,5-diacetamido-2,4,6- triiodobenzoate
  • volume of solvent added was 100 mL, ' with respect to 100 L solvent; * * measured with a Malvern Zetasizer 4, "diameter (%) based on volume distribution, wherein at least about 10%, 50%, or 90%, as indicated, of the particles have the specified number average particle size.
  • volume of solvent added was 100 mL, ' with respect to 100 mL solvent; measured with a Malvern Zetasizer 4, ' 'diameter on volume %.
  • volume of solvent added was 100 mL; ' with respect to 100 mL solvent; * * measured with a Malvern Zetasizer 4, "diameter (%) based on volume distribution, wherein at least about 10%, 50%, or 90%, as indicated, of the particles have the specified number average particle size.
  • T 5 60°C or 1 25 °C
  • Example 5 This example illustrates production of the ethyl
  • An ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl
  • 3,5-diacetamido-2,4,6-triiodobenzoate ?D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) PluronicTM F-68 in water (pH 4.20). About 1 to 10 mg 1 -octanol was added as a defoaming agent. The nanocomposite mixture was sonicated for 5 to 10 minutes to form a stable and homogeneous ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation.
  • the median particle size of the dispersion measured by the laser light scattering method using Horiba LA-900 was 255 nm, and all the particles in the dispersion maintained a size of less than 400 nm.
  • Example 6 This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/lgepal CO-520 ® formulation 1 , which is produced in the context of the present invention.
  • a ethyl 3,5-diacetamido-2,4, 6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate: ⁇ D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) 4- (C 9 H 19 )C 6 H 4 O(CH 2 CH 2 O) 4 CH 2 CH 2 OH (Igepal CO-520 ® ; purchased from Aldrich Chemical Co., Inc., Catalog ft 23,864-3) in water.
  • Example 5 About 1 to 10 mg 1 -octanol was added as a defoaming agent. As described in Example 5, the formulation was sonicated and the particle size was measured. The median particle size of the dispersion was 205 nm and all the particles in the dispersion maintained a size of less than 400 nm.
  • This example illustrates production of the ethyl - 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/lgepal CO-520 ® formulation 2, which is produced in the context of the present invention.
  • a CMP-1 nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:D-Mannitol ( 1 :2 wt.%) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) Igepal CO-520 ⁇ in water. About 1 to 10 mg 1 -octanol was added as a defoaming agent. As described in example 6, the formulation was sonicated and the particle size was measured. The median particle size of the dispersion was 295 nm, and all the particles in the dispersion maintained a size less than 400 nm.
  • This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/Brij ® 30 formulation, which is produced in the context of the present invention.
  • a ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate: ?-D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) C 12 H 25 (OCH 2 CH 2 ) 4 OH (Brij ® 30; purchased from Aldrich Chemical
  • This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/TetronicTM 908 formulation, which is produced in the context of the present invention.
  • This example illustrates certain applications of the present invention for the preparation of naproxen-co ⁇ taining nanoparticles.
  • Solutions of naproxen and host matrices such as ethyl cellulose, sucrose, glucose, and D-mannitol in alcohol, water, DMF, and DMSO were spray dried using the spray dryer described in Example 1 .
  • the size of the atomized droplets was about 1 -5 ⁇ m, and the maximum spray drying temperature was 1 50°C.
  • Table 7 shows the naproxen nanocomposite formulations prepared by this method. The particle size was measured using a Shimadzu SALD-2001 laser diffraction particle size analyzer.
  • Naproxen nanoparticle formulations were prepared by dispersing the nanocomposite powders in water saturated with naproxen and 0.1 % (W/V) Brij ® 30, at pH 2.5 and sonicating for 5 min. The temperature of these dispersions during preparation and particle size analysis were maintained below 10°C.
  • naproxen nanoparticles of less than 400 nm resulted depending on the sugar selected as matrix.
  • sucrose, glucose, and D-mannitol provided nanoparticles of less than 400 nm.
  • An x-ray diffraction analysis using standard methods was done for the 5 g naproxen/5 g ethyl cellulose nanocomposite, which was prepared using the spray drying equipment described in Example 1 .
  • This example illustrates production of naproxen nanoparticles using various matrices.
  • Each of the matrices used in the above-described process to prepare nanoparticles resulted in particles of less than 400 nm.
  • This example illustrates the effect of varying the concentration of the agent in a solution for the production of drug nanoparticles on the median size of the resultant particles.
  • Nanoparticles that included ethyl 3,5-diacetamido-2,4,6- triiodobenzoate as the agent were prepared in accordance with the method set forth in Example 2, but wherein the weight of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate included in the solution per 1 00 mL of 1 2 MPO varied 2 g to 20 g. Median particle size was measured as noted above. The results are shown in the graph of Fig.
  • This example illustrates the effect of varying the concentration of surfactant in a solution for the production of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticles on the median size of the resultant particles.
  • Nanoparticles that included ethyl 3, 5-diacetamido-2,4,6- triiodobenzoate as the agent were prepared in accordance with the method set forth in Example 2, but wherein the weight of surfactant (PluronicTM F-68) included in the solution per 100 mL of 12 MPO varied from 0 g to 1 .5 g. Median particle size was measured as noted above. The results are shown in the graph of Fig. 5, wherein the y-axis is labeled Median Particle Size (nm) and the x-axis is labeled Weight of PluronicTM F-68 (g) /100 mL 1 2 MPO.
  • Example 14 This example illustrates the effect of sonication of spray dried particles in the presence of surfactant to produce nanopart.cles.
  • CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
  • Spray dried powders containing 10 g or 5 g ethyl 3 5-diace,amido-2,4,6-triiodobenzoate per 100 mL 12 MPO were prepared in accordance with Example 2.
  • the resulting powders were 25 analyzed by x-ray diffraction, using standard procedures. As can be seen in Fig. 7. wherein the y-axis is labeled Relative Intensity and the x-axis is labeled Degrees Two Theta, the x-ray diffraction results indicate no compositional differences between the untreated powder and the spray dried powders prepared from ethyl 3,5-diacetamido-2,4,6-triiodobenzoate in 1 2 MPO solutions.

Abstract

La présente invention se rapporte à un procédé de synthèse de nanoparticules consistant à combiner un agent et une matrice pour obtenir un mélange composite, et à sécher par pulvérisation ce mélange composite, les nanoparticules ayant une grosseur inférieure à 5000 nm. Les agents appropriés qui peuvent être formulés dans les nanoparticules, dans le contexte de la présente invention, sont des agents thérapeutiques et de diagnostic, des agents cosmétiques, colorants, photographiques, alimentaires, pesticides et autres.
PCT/US1996/016417 1995-10-13 1996-10-11 Synthese de nanoparticules medicamenteuses par sechage par pulverisation WO1997013503A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96939455A EP0862420A4 (fr) 1995-10-13 1996-10-11 Synthese de nanoparticules medicamenteuses par sechage par pulverisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US519495P 1995-10-13 1995-10-13
US60/005,194 1995-10-13

Publications (2)

Publication Number Publication Date
WO1997013503A1 WO1997013503A1 (fr) 1997-04-17
WO1997013503A9 true WO1997013503A9 (fr) 1997-07-31

Family

ID=21714643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/016417 WO1997013503A1 (fr) 1995-10-13 1996-10-11 Synthese de nanoparticules medicamenteuses par sechage par pulverisation

Country Status (2)

Country Link
EP (1) EP0862420A4 (fr)
WO (1) WO1997013503A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
GB9710604D0 (en) * 1997-05-22 1997-07-16 Nycomed Imaging As Contrast media
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
CA2217095A1 (fr) * 1997-10-22 1999-04-22 Hydro-Quebec Nanocomposites a interfaces activees prepares par broyage mecanique d'hydrures de magnesium et usage de ceux-ci pour le stockage d'hydrogene
DE19920555B4 (de) * 1999-05-05 2004-08-26 Cognis Deutschland Gmbh & Co. Kg Verwendung von nanoskaligen Metallseifen
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE60020732T2 (de) 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CN1830536A (zh) 2000-05-16 2006-09-13 明尼苏达大学评议会 采用多喷嘴喷射产生大批生产量的颗粒
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6541030B2 (en) * 2000-09-27 2003-04-01 Verion Inc. Instant water dissolvable encapsulate and process
WO2002082900A1 (fr) 2001-03-30 2002-10-24 Rhodia Inc. Suspension aqueuse de nanoparticules comprenant un ingredient agrochimique actif
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
US7247338B2 (en) 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
WO2003032959A1 (fr) * 2001-10-15 2003-04-24 Bosch William H Compositions nanoparticulaires comprenant des noyaux inorganiques
ATE401058T1 (de) 2001-11-01 2008-08-15 Nektar Therapeutics Sprühtrocknungsverfahren
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DE60329188D1 (de) 2002-08-12 2009-10-22 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0310300D0 (en) * 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
EP1635786A2 (fr) 2003-05-28 2006-03-22 Nektar Therapeutics Sechage par pulverisation d'une solution aqueuse alcoolique pour la fabrication d'une microparticule contenant un principe actif insoluble dans l'eau et ayant un enrobage partiel ou complet comprenant un acide amine ou un phospholipide
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10351004A1 (de) 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
WO2006083326A2 (fr) 2004-08-07 2006-08-10 Cabot Corporation Fabrication d'une dispersion gazeuse de nanoparticules, et produits contenant des nanoparticules et traitement de ceux-ci
US7829000B2 (en) 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
EP1868578A2 (fr) * 2005-03-23 2007-12-26 Elan Pharma International Limited Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
CN101277682B (zh) 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
FR2891275B1 (fr) * 2005-09-26 2007-11-16 Commissariat Energie Atomique Procede de fabrication de compositions comprenant des nanoparticules d'un elememnt ou compose chimique dispersees dans une matrice organique
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US7951428B2 (en) 2006-01-31 2011-05-31 Regents Of The University Of Minnesota Electrospray coating of objects
US9248217B2 (en) 2006-01-31 2016-02-02 Nanocopocia, LLC Nanoparticle coating of surfaces
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008034273A1 (fr) 2006-09-22 2008-03-27 Mivital Ag Émulsions contenant de la gomme arabique
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
WO2008080037A2 (fr) 2006-12-21 2008-07-03 Isp Investments Inc. Caroténoïdes à biodisponibilité améliorée
EP2125938A2 (fr) 2007-01-26 2009-12-02 Isp Investments Inc. Procédé de traitement de formulation pour produire des produits séchés pour une pulvérisation
WO2008135855A2 (fr) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticules contenant un inhibiteur de la protéine de transfert d'ester de cholestéryle et un polymère non ionisable
WO2008135828A2 (fr) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticules comprenant un médicament, de l'éthylcellulose et un sel biliaire
WO2008149230A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
EP2162120B1 (fr) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable
WO2009073215A1 (fr) 2007-12-06 2009-06-11 Bend Research, Inc. Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
WO2009073216A1 (fr) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
EP2378869A2 (fr) * 2008-12-18 2011-10-26 Basf Se Dispersion aqueuse contenant des particules de pesticides et un saccharide en solution
JP2013503166A (ja) * 2009-08-25 2013-01-31 カーディオカイン・バイオファーマ・エルエルシー 不溶性剤を送達するための組成物
WO2013132457A2 (fr) 2012-03-07 2013-09-12 National Institute Of Pharmaceutical Education And Research (Niper) Compositions de dispersions de solides nanocristallins et leur procédé de préparation
RU2561686C1 (ru) * 2014-04-01 2015-08-27 Александр Александрович Кролевец Способ инкапсуляции аспирина в ксантановой камеди
EP3586827A1 (fr) 2018-06-29 2020-01-01 Consejo Superior de Investigaciones Cientificas (CSIC) Formulation pharmaceutique présentant une solubilité et une biodisponibilité améliorées
CN114886856A (zh) * 2022-06-09 2022-08-12 山西辅仁恒峰药业有限公司 一种奥司他韦纳米干混悬剂的制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.

Similar Documents

Publication Publication Date Title
WO1997013503A9 (fr) Synthese de nanoparticules medicamenteuses par sechage par pulverisation
WO1997013503A1 (fr) Synthese de nanoparticules medicamenteuses par sechage par pulverisation
JP6025706B2 (ja) 微小粒子またはナノ粒子を生成する方法および装置
Plakkot et al. Comminution of ibuprofen to produce nano-particles for rapid dissolution
Caliceti et al. Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques
RU2186562C2 (ru) Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5718919A (en) Nanoparticles containing the R(-)enantiomer of ibuprofen
FI108333B (fi) Menetelmõ nanopartikkelikoostumusten valmistamiseksi
Kaialy et al. Recent advances in the engineering of nanosized active pharmaceutical ingredients: promises and challenges
US6756062B2 (en) Preparation of drug particles using evaporation precipitation into aqueous solutions
CA2458889C (fr) Procede de precipitation de particules medicamenteuses
Yadav et al. Nanosuspension: A promising drug delivery system
US20050139144A1 (en) Method for the production and the use of microparticles and nanoparticles by constructive micronisation
US20120231093A1 (en) Method for preparing nano-scale or amorphous particle using solid fat as a solvent
Li et al. Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation
Zhang et al. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies
Dan et al. Microcrystalline cellulose-carboxymethyl cellulose sodium as an effective dispersant for drug nanocrystals: A case study
Matos et al. Single-step coprecipitation and coating to prepare curcumin formulations by supercritical fluid technology
Pu et al. Ultrafine clarithromycin nanoparticles via anti-solvent precipitation in subcritical water: Effect of operating parameters
JP2007503399A (ja) 生物活性化合物の粒子サイズの低減
Vatanara Spray drying of nanoparticles to form fast dissolving glipizide
Sheng et al. Continuous and scalable process for the production of hollow crystals of a poorly water-soluble active pharmaceutical ingredient for dissolution enhancement and inhaled delivery
Wang et al. A novel strategy to produce highly stable and transparent aqueous ‘nanosolutions’ ofwater-insoluble drug molecules
Raula et al. Aerosol flow reactor method for the synthesis of multicomponent drug nano-and microparticles
Jaspreet et al. Development of Nanocrystal Formulation with Improved Dissolution. J
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载